Enter inventor name

Average Co-Inventor Count = 2.6

ph-index = 13

Forward Citations = 659(Granted Patents)

Location History:

Weston, MA (US) (1977 - 1994)
New York, NY (US) (1994)
Princeton, NJ (US) (1995)
late of Salisbury, NH (US) (2001)
Salisbury, NH (US) (1993 - 2003)

Company Filing History:

17 out of 2,893

The General Hospital Corporation

Massachusetts General Hospital Corporation

Bristol-myers Squibb Compnay

where one patent can have more than one assignee

Years Active: 1977-2003

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6576431 - Antibodies that bind to &agr;2-antiplasmin crosslinked to fibrin which do not inhibit plasma &agr;2-antiplasmin (2003-06-10),

2. 6280730 - Antibodies that bind to &agr;2-antiplasmin crosslinked to fibrin which do not inhibit plasma &agr;2-antiplasmin (2001-08-28),

3. 6258557 - Smooth muscle cell LIM promoter (2001-07-10),

4. 6248933 - Cellular basis of vascular-graft stenosis (2001-06-19),

5. 6136953 - Smooth muscle cell LIM protein (2000-10-24),

6. 5888765 - Endothelial-cell specific promoter (1999-03-30),

7. 5831031 - Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which (1998-11-03),

8. 5811265 - Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically (1998-09-22),

9. 5767262 - Smooth muscle cell LIM protein (1998-06-16),

10. 5675062 - Cellular basis of transplant arteriosclerosis in mice (1997-10-07),

11. 5620688 - Methods of inhibiting the activation of Factor XIII (1997-04-15),

12. 5609869 - Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically (1997-03-11),

13. 5582862 - Antibodies that bind to .alpha.2-antiplasmin crosslinked to fibrin which (1996-12-10),

14. 5571523 - Antioxidant-induced apoptosis in vascular smooth muscle cells (1996-11-05),

15. 5453269 - Heterobifunctional antibodies having dual specificity for fibrin and (1995-09-26),

Title: Innovations and Contributions of Edgar Haber in Antibody Therapy

Introduction

Edgar Haber, based in Salisbury, NH, is an esteemed inventor with a remarkable portfolio of 32 patents. His innovative work primarily focuses on therapies aimed at addressing critical medical conditions, particularly myocardial infarction and blood clots.

Latest Patents

One of his significant recent patents includes the development of antibodies that bind to α2-antiplasmin crosslinked to fibrin, which do not inhibit plasma α2-antiplasmin. This groundbreaking invention provides a treatment for myocardial infarction and enhances clot lysis by administering an antibody directed toward α2-antiplasmin crosslinked to fibrin, in conjunction with a thrombolytic agent. This therapeutic approach significantly contributes to advancing medical treatments for patients experiencing severe blood clotting issues.

Career Highlights

Throughout his career, Edgar Haber has been associated with prestigious institutions such as The General Hospital Corporation and the President and Fellows of Harvard College. His role in these organizations has been instrumental in pushing the boundaries of medical research and therapeutic innovations.

Collaborations

Edgar has collaborated with notable colleagues, including Gary R. Matsueda and Guy L. Reed. These partnerships have led to further advancements in the field of antibody research and the development of innovative medical therapies.

Conclusion

Edgar Haber's contributions to the field of biotechnology, particularly in the area of antibody therapy, showcase his dedication to innovation and improving patient outcomes. His extensive patent portfolio not only reflects his inventive spirit but also highlights the significant impact his work has on modern medical treatments.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com